MK-4830 / Xoma, Merck (MSD), Agenus 
Welcome,         Profile    Billing    Logout  

18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK-4830 / Merck (MSD)
2021-005458-27: A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High Grade Serous Ovarian Cancer Estudio de fase II, aleatorizado de pembrolizumab y quimioterapia, con o sin MK-4830, un tratamiento neoadyuvante para el carcinoma seroso de ovario de alto grado.

Not yet recruiting
2
160
Europe
MK-4830, MK-4830, Solution for infusion, KEYTRUDA (pembrolizumab,MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
First-line treatment of advanced High Grade Serous Ovarian Cancer Tratamiento de primera línea del Carcinoma seroso de ovario de alto grado avanzado, High Grade Serous Ovarian Cancer Carcinoma seroso de ovario de alto grado, Diseases [C] - Cancer [C04]
 
 
MK-4830-002, NCT05446870: Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer

Active, not recruiting
2
160
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Paclitaxel, TAXOL®, Carboplatin, PARAPLATIN®, Avastin, Bevacizumab, Zirabev, MVASI, AYBINTIO, Versavo, Onbevezy, OYAVAS, ALYMSYS, Avegra, MK-4830, Docetaxel
Merck Sharp & Dohme LLC
High-grade Serous Ovarian Carcinoma, Ovarian Carcinoma
12/23
12/24
KEYSTEP-008, NCT04895722 / 2020-005114-18: Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/)

Active, not recruiting
2
320
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, Keytruda®, Pembrolizumab/Quavonlimab, MK-1308A, Pembrolizumab/Favezelimab, MK-4280A, Pembrolizumab/Vibostolimab, MK-7684A, MK-4830
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Colorectal Cancer
10/25
11/25
KEYNOTE-B99, NCT04924101 / 2020-005649-17: Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ )

Active, not recruiting
2
120
Europe, Canada, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, SCH 900475, MK-4830, Boserolimab, MK-5890, Lenvatinib, LENVIMA®, KISPLYX®, MK-7902, E7080, Etoposide, Etopophos®, Vepesid®, Toposar®, VP-16, Etoposide phosphate, Cisplatin, Platinol-AQ, Platinol, CDDP, Carboplatin, Paraplatin, Paraplatin NovaPlus, Carboplatin N+ Novaplus, Carboplatin Novaplus, PremierPro Rx Carboplatin
Merck Sharp & Dohme LLC
Small Cell Lung Cancer
07/26
07/26
KEYMAKER-U01A, NCT04165070 / 2020-001626-56: KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/)

Hourglass Jan 2022 - Dec 2022 : Of KEYNOTE-01A trial for advanced NSCLC
Active, not recruiting
2
360
Europe, US, RoW
Pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®, Carboplatin, PARAPLATIN®, Paclitaxel, ABRAXANE®, Pemetrexed, ALIMTA®, Vibostolimab, MK-7684, Boserolimab, MK-5890, MK-4830, MK-0482
Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
02/39
02/39
KEYMAKER-U01C, NCT04165096 / 2020-001629-29: KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/)

Active, not recruiting
2
135
Europe, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, SCH 900475, Boserolimab, MK-5890, MK-4830, diphenhydramine, acetaminophen, MK-0482
Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
02/32
02/32
KEYMAKER-U01B, NCT04165083 / 2020-001627-14: KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/)

Active, not recruiting
2
120
Europe, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, SCH 900475, MK-4830, MK-0482
Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
09/25
09/25
2019-003610-13: A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Substudy 03B

Not yet recruiting
1/2
370
Europe
Lenvatinib, MK-1308/Pembrolizumab, MK-4280/Pembrolizumab, MK-4830, MK-6482, E7080, MK-1308A, MK-4280A, MK-4830, MK-6482, Solution for infusion, Capsule, hard, Film-coated tablet, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, Merck Sharp & Dohme LLC
Renal Cell Carcinoma, Renal Cell Carcinoma (Kidney Cancer), Diseases [C] - Cancer [C04]
 
 
2021-005443-76: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK 3475) in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment. Studio con disegno a ombrello, di fase 1/2 in aperto, di molecole sperimentali in associazione a Pembrolizumab (MK-3475) in partecipanti con tumore esofageo avanzato precedentemente esposti al trattamento con PD-1/PD-L1

Not yet recruiting
1/2
90
Europe
-, MK-4830, Lenvatinib, [MK-3475], [MK-4830], [E7080], [-], Solution for infusion, Capsule, hard, Concentrate for solution for injection/infusion, KEYTRUDA® (Pembrolizumab, MK-3475), Paclitaxel, Irinotecan
MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma Carcinoma a cellule squamose dell'esofago, Advance esophageal carcinoma Carcinoma esofageo avanzato, Diseases [C] - Cancer [C04]
 
 
2021-005405-26: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment Studio con disegno a ombrello, di fase 1/2 in aperto, di molecole sperimentali in associazione a Pembrolizumab (MK-3475) in partecipanti con tumore esofageo avanzato naïve al trattamento con PD-1/PD-L1 (KEYMAKER-U06)

Not yet recruiting
1/2
120
Europe
-, MK-4830, favezelimab / pembrolizumab, Lenvatinib, [MK-3475], [MK-4830], [MK-4280A], [E7080], [-], Solution for infusion, Capsule, hard, Concentrate for solution for injection/infusion, KEYTRUDA® (Pembrolizumab, MK-3475), Paclitaxel, Irinotecan
MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma (ESCC) Carcinoma a cellule squamose dell'esofago (ESCC), Advance esophageal carcinoma Carcinoma esofageo avanzato, Diseases [C] - Cancer [C04]
 
 
KEYMAKER-U06 substudy 06A, NCT05342636: A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Active, not recruiting
1/2
120
Europe, Japan, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Coformulation favezelimab/pembrolizumab, MK-4280A, MK-4830, anti-immunoglobulin-like transcript 4 (ILT4), Lenvatinib, MK-7902, LENVIMA®, Irinotecan, Paclitaxel
Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma (ESCC)
11/24
09/26
NCT05319730: A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Recruiting
1/2
200
Europe, Japan, RoW
Paclitaxel, Irinotecan, Pembrolizumab, MK-3475, KEYTRUDA®, MK-4830, anti-immunoglobulin-like transcript 4 (anti-ILT4), Lenvatinib, MK-7902, LENVIMA®, Sacituzumab tirumotecan, SKB264, MK-2870, Antihistamine, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent)
Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma
11/26
09/28
KEYMAKER-U03B, NCT04626518: Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)

Active, not recruiting
1/2
370
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, MK-4830, Belzutifan, MK-6482, WELIREG™, Lenvatinib, MK-7902, E7080, LENVIMA®, Pembrolizumab/Quavonlimab, MK-1308A, Favezelimab/Pembrolizumab, MK-4280A
Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
09/25
09/25
KEYNOTE-B98, NCT04938817 / 2020-005628-12: Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Investigational Agents for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/)

Active, not recruiting
1/2
80
Europe, Canada, US, RoW
coformulation pembrolizumab/quavonlimab, MK-1308A, lenvatinib, LENVIMA®, KISPLYX®, MK-7902, E7080, MK-4830, coformulation favezelimab/pembrolizumab, MK-4280A
Merck Sharp & Dohme LLC
Small Cell Lung Carcinoma
11/26
11/26
KEYMAKER-U02 Substudy 02C, NCT04303169: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

Active, not recruiting
1/2
90
Europe, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Vibostolimab, MK-7684, Gebasaxturev, Coxsackievirus A21 (CVA21), Formerly known as CAVATAK®, CAV21, V937, MK-4830, Favezelimab + Pembrolizumab, MK-4280A, ATRA, Tretinoin, Vesanoid®
Merck Sharp & Dohme LLC
Melanoma
04/30
04/30
NCT06413095: PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

Completed
1
13
US
Pembrolizumab, Keytruda, MK-3475, MK-0482 + Pembrolizumab, MK-4830 + Pembrolizumab
Presage Biosciences, Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma
06/23
06/23
MK-4830-001, NCT03564691: Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors

Checkmark Data from a trial in combination with MK-4830 for solid tumor
Sep 2020 - Sep 2020: Data from a trial in combination with MK-4830 for solid tumor
Active, not recruiting
1
442
Europe, Canada, Japan, US, RoW
MK-4830, Pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®, Carboplatin, Paraplatin, Pemetrexed, ALIMTA®, Pleumet, Pemecad, Lenvatinib, LENVIMA®, Lenvanix, Paclitaxel, Nov-Onxol, Onxol, Paclitaxel Novaplus, Taxol, Cisplatin, Platinol®, Platinol®-AQ, CDDP, MK-4830A
Merck Sharp & Dohme LLC
Neoplasms
09/25
09/25
NCT04541108: Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Recruiting
1
15
US
Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, Pembrolizumab, Keytruda, MK-3475
Presage Biosciences, Merck Sharp & Dohme LLC
Solid Tumor
12/31
12/31

Download Options